IntegraMed America, Incorporation. : IntegraMed American Acquisition Lawsuit Investigation Concerning Breach of Fiduciary Duties in Sagard Capital Acquisition Announced by Gilman Law LLP
06/20/2012| 03:45pm US/Eastern
Recommend:
Shareholder
Rights Law Firm Gilman Law LLP has commenced a breach of fiduciary
duty investigation on behalf of current shareholders of IntegraMed
America, Inc. (Nasdaq: INMD)
("IntegraMed") and other violations of state law by the board of
directors of IntegraMed relating to the proposed buyout of the company
by affiliates of the investment firm Sagard Capital Partners, L.P.
("Sagard Capital"). Gilman Law LLP's investigation focuses on
determining whether the board breached its fiduciary duties by failing
to maximize shareholder value in the proposed InregraMed Acquisition.
Join the IntegraMed American Acquisition Lawsuit
About the IntegraMed American Acquisition Lawsuit
IntegraMed announced on June 11, 2012, that it had entered into a
definitive agreement allowing Sagard Capital to acquire IntegraMed
America for approximately $169.5 million. Under the terms of the
IntegraMed buyout transaction, IntegraMed shareholders will receive
$14.05 for each share of IntegraMed common stock held. According to
sources, analysts have set a mean price target of $15.50. At least one
analyst has set a high price target of $17.00 per share.
About the Shareholder Rights Law Firm Gilman Law LLP
IntegraMed shareholders who would like to learn more about the
investigation may contact the Securities
Attorneys at Gilman Law LLP for a free consultation, with no cost or
obligation to you. Our Securities Attorneys have over 33 years of
experience in securities litigation, securities arbitration, mergers &
acquisitions, shareholder disputes, and other types of violations of
securities laws.
Gilman Law LLP
Kenneth Gilman, Esq., 888-252-0048
consultations@gilmanlawllp.com
© Business Wire 2012
Recommend :
